Synthesis and Antimicrobial Activity of New Heteroaryl(aryl) Thiazole Derivatives Molecular Docking Studies
Victor Kartsev,
Athina Geronikaki,
Alexander Zubenko,
Anthi Petrou,
Marija Ivanov,
Jasmina Glamočlija,
Marina Sokovic,
Lyudmila Divaeva,
Anatolii Morkovnik,
Alexander Klimenko
Affiliations
Victor Kartsev
InterBioScreen, 119019 Moscow, Russia
Athina Geronikaki
School of Health, Faculty of Pharmacy, Aristotle University, 54124 Thessaloniki, Greece
Alexander Zubenko
North-Caucasian Zonal Research Veterinary Institute, 346406 Novocherkassk, Russia
Anthi Petrou
School of Health, Faculty of Pharmacy, Aristotle University, 54124 Thessaloniki, Greece
Marija Ivanov
Mycological Laboratory, Department of Plant Physiology, Institute for Biological Research “Siniša Stanković”, National Institute of Republic of Serbia, University of Belgrade, 11060 Belgrade, Serbia
Jasmina Glamočlija
Mycological Laboratory, Department of Plant Physiology, Institute for Biological Research “Siniša Stanković”, National Institute of Republic of Serbia, University of Belgrade, 11060 Belgrade, Serbia
Marina Sokovic
Mycological Laboratory, Department of Plant Physiology, Institute for Biological Research “Siniša Stanković”, National Institute of Republic of Serbia, University of Belgrade, 11060 Belgrade, Serbia
Lyudmila Divaeva
Institute of Physical and Organic Chemistry, Southern Federal University, 344090 Rostov-on-Don, Russia
Anatolii Morkovnik
Institute of Physical and Organic Chemistry, Southern Federal University, 344090 Rostov-on-Don, Russia
Alexander Klimenko
North-Caucasian Zonal Research Veterinary Institute, 346406 Novocherkassk, Russia
Herein, we report the design, synthesis, and evaluation of the antimicrobial activity of new heteroaryl (aryl) thiazole derivatives. The design was based on a molecular hybridization approach. The in vitro evaluation revealed that these compounds demonstrated moderate antibacterial activity. The best activity was achieved for compound 3, with MIC and MBC in the range of 0.23–0.7 and 0.47–0.94 mg/mL, respectively. Three compounds (2, 3, and 4) were tested against three resistant strains, namely methicillin resistant Staphylococcus aureus, P. aeruginosa, and E. coli, which showed higher potential than the reference drug ampicillin. Antifungal activity of the compounds was better with MIC and MFC in the range of 0.06–0.47 and 0.11–0.94 mg/mL, respectively. The best activity was observed for compound 9, with MIC at 0.06–0.23 mg/mL and MFC at 0.11–0.47 mg/mL. According to docking studies, the predicted inhibition of the E. coli MurB enzyme is a putative mechanism of the antibacterial activity of the compounds, while inhibition of 14a-lanosterol demethylase is probably the mechanism of their antifungal activity.
